SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Tuesday reported fiscal second-quarter profit of $24 million.

On a per-share basis, the Salt Lake City-based company said it had profit of 32 cents. Earnings, adjusted for severance costs and costs related to mergers and acquisitions, were 40 cents per share.

The results surpassed Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 35 cents per share.

The molecular diagnostic company posted revenue of $184.4 million in the period, which also beat Street forecasts. Analysts expected $183.1 million, according to Zacks.

For the current quarter ending in March, Myriad expects its per-share earnings to range from 38 cents to 40 cents.

The company said it expects revenue in the range of $180 million to $185 million for the fiscal third quarter.

Myriad expects full-year earnings in the range of $1.50 to $1.55 per share, with revenue ranging from $730 million to $740 million.

Myriad shares have increased 12 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $38.12, an increase of 39 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at http://www.zacks.com/ap/MYGN

_____

Keywords: Myriad Genetics, Earnings Report